<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704676</url>
  </required_header>
  <id_info>
    <org_study_id>CA125</org_study_id>
    <nct_id>NCT02704676</nct_id>
  </id_info>
  <brief_title>CA-125 and Severity of Pre-Eclampsia</brief_title>
  <official_title>CA-125 and Severity of Pre-Eclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Aim of this study is to determine the relationship between serum concentrations of cancer
      antigen-125 (CA-125) and pre-eclampsia severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the source of CA-125 during pregnancy is the fetal chorion, amniotic fluid, and
      maternal decidua, the perinatal dynamics of maternal serum CA-125 requires clarification.
      Clinical studies of CA-125 levels and its function in hypertensive pregnant patients are
      limited and offered contradictory results (Cebesoy et al., 2009).

      And so we investigate CA-125 in normal pregnancy and in pre-eclampsia, comparing mild and
      sever pre-eclampsia to determine relationship of CA-125 and severity of the disease.

      Patients will be divided in three groups:

        -  Control: 40 normal healthy pregnant women attending the ER in labor.

        -  Mild pre-eclampsia: 40 patients fulfilling the following criteria.

             -  Blood pressure: systolic blood pressure &gt;140 and &lt;160 , Diastolic blood pressure
                &gt;90 and &lt;110

             -  Proteinuria: 300 mg (+) assessed by urine urignost 3AÂ® (urine strips from DIALAB).

             -  No symptoms of severity as headache.

             -  Normal investigations for different organ function (as liver and kidney function).

        -  Severe pre-eclampsia :40 patients fulfilling anyone or more of the following criteria
           (The American College of Obstetricians and Gynecologists, 2010)(ACOG):

             -  Systolic blood pressure &gt; 160 mmHg

             -  Diastolic blood pressure &gt; 110 mmHg (on two occasions at least 6 hours apart while
                the patient is on bed rest)

             -  Proteinuria of 5000mg (5g) or higher on a 24-hour urine collection or at least 3+
                on two random urine samples collected at least 4 hours apart

             -  Oliguria &lt; 500 mL urine output in 24 hours

             -  Cerebral or visual functional disturbances (cns irritability)

             -  Pulmonary edema or cyanosis (not due to excessive intravenous volume replacement)

             -  Epigastric or right-upper quadrant abdominal pain

             -  Impaired liver function on laboratory analysis (elevated aspartate aminotransferase
                (AST), alanine amino transferase(ALT), or lactate dehydrogenase(LDH))

             -  Thrombocytopenia (platelet count &lt; 150,000/uL)

             -  Fetal growth restriction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>increase serum CA-125 in pre-eclamptic patients</measure>
    <time_frame>1 year</time_frame>
    <description>measuring serum CA-125</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>control patients</arm_group_label>
    <description>normal pregnant women, 3rd trimester</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mild pre-eclampsia</arm_group_label>
    <description>patients with albuminuria +1 and blood pressure &gt;140/90 and &lt;160/110</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sever pre-eclampsia</arm_group_label>
    <description>patients diagnosed as sever pre-eclampsia according to criteria done by ACOG</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>marker(CA-125)</intervention_name>
    <description>measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)</description>
    <arm_group_label>control patients</arm_group_label>
    <arm_group_label>mild pre-eclampsia</arm_group_label>
    <arm_group_label>sever pre-eclampsia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population comprises pregnant women once diagnosed pre-eclampsia, attending to
        Ain Shams University Maternity Hospital, or for antinatal care of the corrosponding
        gestational age.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  pregnant women 3rd trimester

          -  any age

          -  medically free at least by history

          -  signs and or symptoms of pre-eclampsia

        Exclusion Criteria:

          -  Other causes elevate CA-125 as: ovarian cancer, endometrial cancer, breast cancer and
             benign conditions as: endometriosis and liver cirrhosis.

        Chronic hypertension

          -  Diabetes Mellitus (DM)

          -  Liver diseases

          -  Thyroid disorders

          -  Kidney diseases

          -  Cardiac diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Tawfek, Pofessor</last_name>
    <role>Study Director</role>
    <affiliation>ain-shams university , cairo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa M Ibrahim, MBBCH</last_name>
    <phone>01007378387</phone>
    <email>dr.marwa_2010@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed M Bahaa eldin, A.Professor</last_name>
    <phone>+20 1111700556</phone>
    <email>abahaa0503@med.asu.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Cebesoy FB, Balat O, Dikensoy E, Kalayci H, Ibar Y. CA-125 and CRP are elevated in preeclampsia. Hypertens Pregnancy. 2009 May;28(2):201-11. doi: 10.1080/10641950802601187.</citation>
    <PMID>19437230</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Bahaa Eldin Ahmed</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>CA-125</keyword>
  <keyword>Pre-Eclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

